Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Avadel Shares Rise and Shine on Positive Phase 3 Narcolepsy Study Findings

Avadel Pharmaceuticals' shares traded 25% higher reaching a new 52-week high price after the company reported positive topline results from its Pivotal Phase 3 REST-ON trial of FT218 for the treatment of excessive daytime sleepiness and cataplexy in narcolepsy patients. ...
Streetwise Reports | April 28, 2020 |

Fed Cut Equities Stimulus 86% This Week and Stocks Are Falling

What happens to the global markets when the US Fed begins to weaken stimulus activity and when the global markets must begin to function on their own? Are the global markets capable of sustaining current price levels without the Fed supporting them? A recent news article s...
Chris Vermeulen | May 1, 2020 |

Silver Offers A Golden Opportunity To Preserve Soon To Be Destroyed Value

The fundamentals for silver and gold are very strong, and with all the massive bailouts and stimulus, which have increased debt levels, they are just getting stronger. Until a significant portion of these debts is repaid or defaulted on, it would be foolish to talk about a to...
Hubert Moolman | July 3, 2020 |

Axsome Therapeutics Investors Awaken to Positive Outcome in Phase 2 Narcolepsy Trial

Axsome Therapeutics shares traded 14% higher today after the company reported that its narcolepsy drug candidate AXS-12 achieved its primary endpoint in the Phase 2 CONCERT Study. This morning before U.S. markets opened, clinical-stage biopharmaceutical company Axsom...
Streetwise Reports | December 4, 2019 |

What if we threw a Cold War and nobody came?

Russia just can’t seem to keep itself from stepping on America’s toes - the foot belonging to Latin American countries that are within the American sphere of influence known historically as the Monroe Doctrine. On Sunday two Russian militar...
Richard (Rick) Mills | March 27, 2019 |

AOL, Inc. (AOL): Can it fly in the face of skepticism?

Late last week, analysts at Macquarie launched coverage of AOL, Inc. ( NYSE: AOL , Stock Forum ) with a "neutral" rating and a $27 price target, essentially implying that they don't expect the stock to move much higher in the near future. Nevertheless, unenthusiastic ra...
Andrea Kramer | October 28, 2012 |

Avadel Pharma Shares Up 30% Upon Acceleration of Phase 3 REST-ON Study

Avadel Pharmaceuticals' shares are trading 30% higher today on news that the FDA agreed to reduce the sample size required for its Phase 3 REST-ON study, accelerating its completion by year-end 2019. Dublin, Ireland-based Avadel Pharmaceuticals Plc (AVDL:NASDAQ) , wh...
Streetwise Reports | September 24, 2019 |

Three Upside and One Downside Risk for Gold

Our base scenario for 2020 is that it might be a worse year for gold than 2019 was. However, there are three major upside (and one downside) risks for the gold market, which could materialize in 2020. Today’s article will introduce you to these potential cataly...
Arkadiusz Sieron | January 24, 2020 |

MyoKardia Shares Get a Jolt from Positive Phase 3 HCM Clinical Trial Results

Shares of MyoKardia traded 60% higher, setting a new 52-week high price, after the company reported that it met all primary and secondary endpoints in the Phase 3 EXPLORER study of mavacamten in treatment of obstructive hypertrophic cardiomyopathy. Clinical-...
Streetwise Reports | May 12, 2020 |

Gold Is Starting to Look Toppy

Bob Moriarty of 321gold urges caution as the gold bulls revive. Gold bulls are coming out of hibernation, with even billionaires talking about how much they like gold. That tends to happen just before a correction. The gold bulls get frothy around the mouth;...
Streetwise Reports | June 25, 2019 |
1 2 3 4 5 6 7 8 9 10